Immuno-Molecular Targeted Therapy Use and Survival Benefit in Patients with Stage IVB Cervical Carcinoma in Commission on Cancer®-Accredited Facilities in the United States

Author:

Sitler Collin A.12,Tian Chunqiao123,Hamilton Chad A.4,Richardson Michael T.5ORCID,Chan John K.6,Kapp Daniel S.7ORCID,Leath Charles A.8,Casablanca Yovanni9,Washington Christina10,Chappell Nicole P.11,Klopp Ann H.12ORCID,Shriver Craig D.2ORCID,Tarney Christopher M.12,Bateman Nicholas W.123,Conrads Thomas P.1213,Maxwell George Larry1213,Phippen Neil T.12,Darcy Kathleen M.123ORCID

Affiliation:

1. Gynecologic Cancer Center of Excellence, Department of Gynecologic Surgery and Obstetrics, Uniformed Services University of the Health Sciences, Walter Reed National Military Medical Center, Bethesda, MD 20889, USA

2. Murtha Cancer Center Research Program, Department of Surgery, Uniformed Services University of the Health Sciences, Walter Reed National Military Medical Center, Bethesda, MD 20889, USA

3. The Henry M. Jackson Foundation for the Advancement of Military Medicine Inc., Bethesda, MD 20817, USA

4. Gynecologic Oncology Section, Women’s Services and The Ochsner Cancer Institute, Ochsner Health, New Orleans, LA 70115, USA

5. Department of Obstetrics and Gynecology, Los Angeles School of Medicine, University of California, Los Angeles, CA 90024, USA

6. Palo Alto Medical Foundation, California Pacific Medical Center, Sutter Health, San Francisco, CA 94010, USA

7. Department of Radiation Oncology, Stanford University School of Medicine, Stanford, CA 94305, USA

8. Division of Gynecologic Oncology, University of Alabama at Birmingham, O’Neal Comprehensive Cancer Center, Birmingham, AL 35249, USA

9. Gynecologic Oncology Division, Levine Cancer Institute, Atrium Health, Charlotte, NC 28204, USA

10. Gynecologic Oncology Division, Stephenson Cancer Center, Oklahoma University Health Sciences Center, Oklahoma City, OK 73104, USA

11. Gynecologic Oncology Division, GW Medical Faculty Associates, George Washington University, Washington, DC 20037, USA

12. Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

13. Women’s Health Integrated Research Center, Women’s Service Line, Inova Health System, Falls Church, VA 22042, USA

Abstract

Purpose: To investigate IMT use and survival in real-world stage IVB cervical cancer patients outside randomized clinical trials. Methods: Patients diagnosed with stage IVB cervical cancer during 2013–2019 in the National Cancer Database and treated with chemotherapy (CT) ± external beam radiation (EBRT) ± intracavitary brachytherapy (ICBT) ± IMT were studied. The adjusted hazard ratio (AHR) and 95% confidence interval (CI) for risk of death were estimated in patients treated with vs. without IMT after applying propensity score analysis to balance the clinical covariates. Results: There were 3164 evaluable patients, including 969 (31%) who were treated with IMT. The use of IMT increased from 11% in 2013 to 46% in 2019. Age, insurance, facility type, sites of distant metastasis, and type of first-line treatment were independently associated with using IMT. In propensity-score-balanced patients, the median survival was 18.6 vs. 13.1 months for with vs. without IMT (p < 0.001). The AHR was 0.72 (95% CI = 0.64–0.80) for adding IMT overall, 0.72 for IMT + CT, 0.66 for IMT + CT + EBRT, and 0.69 for IMT + CT + EBRT + ICBT. IMT-associated survival improvements were suggested in all subgroups by age, race/ethnicity, comorbidity score, facility type, tumor grade, tumor size, and site of metastasis. Conclusions: IMT was associated with a consistent survival benefit in real-world patients with stage IVB cervical cancer.

Funder

Uniformed Services University of the Health Sciences

Publisher

MDPI AG

Reference57 articles.

1. Cancer of the cervix uteri: 2021 update;Bhatla;Int. J. Gynaecol. Obstet. Off. J. Int. Fed. Gynaecol. Obstet.,2021

2. The new (Version 9) American Joint Committee on Cancer tumor, node, metastasis staging for cervical cancer;Olawaiye;CA Cancer J. Clin.,2021

3. National Comprehensive Cancer Network (2023, April 28). Cervical Cancer (Version 1.2023). Available online: https://www.nccn.org/professionals/physician_gls/pdf/cervical.pdf.

4. Prognostic factors for response to cisplatin-based chemotherapy in advanced cervical carcinoma: A Gynecologic Oncology Group Study;Moore;Gynecol. Oncol.,2010

5. Outcomes and toxicities for the treatment of stage IVB cervical cancer;Hwang;Arch. Gynecol. Obstet.,2012

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3